Previous close | 1.2100 |
Open | 1.2200 |
Bid | 1.1600 x 100 |
Ask | 1.2500 x 100 |
Day's range | 1.1900 - 1.2900 |
52-week range | 0.7400 - 1.7600 |
Volume | |
Avg. volume | 760,483 |
Market cap | 50.767M |
Beta (5Y monthly) | 1.09 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.9000 |
Earnings date | 28 Mar 2024 - 10 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.50 |
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference: 10th Annual Immuno-Oncology 360 Conference (IO360)Speaker: Sergio Quezada, PhD, Chief Scientific OfficerPresentation: Targeting Clonal Neoantigens with Precision Cell TherapiesLocation: New Y